Data from Concert Pharmaceuticals' CTP-499 study to be presented at ASN Kidney Week 2011

Concert Pharmaceuticals, Inc. today announced that three abstracts relating to CTP-499, its clinical candidate for the potential treatment of diabetic nephropathy, have been accepted for poster presentations at the American Society of Nephrology's (ASN) Kidney Week 2011. The annual meeting will be held November 8-13, 2011 in Philadelphia, PA. Full abstracts can be viewed online at http://www.asn-online.org/education_and_meetings/kidneyweek/archives/.

The schedule and details for the CTP-499 abstracts and poster presentations at ASN are as follows:

• "Single Ascending Dose Pharmacokinetics, Safety and Tolerability of CTP-499, a Novel Agent Being Investigated for Treatment of Chronic Kidney Disease," Poster Board #: TH-PO359; Thursday November 10; 10am-12pm ET.
• "First Human Exposure Suggests a Unique Metabolic Profile with Multiple Active Species for CTP-499, a Novel Agent for Treatment of Chronic Kidney Disease," Poster Board #: TH-PO358; Thursday November 10; 10am-12pm ET.
• "CTP-499, a Novel Drug for the Potential Treatment of Chronic Kidney Disease, Has Anti-Fibrotic, Anti-Inflammatory, and Anti-Oxidative Activities with In Vivo Efficacy," Poster Board #: FR−PO1836; Friday, November 11; 10am-12pm ET.
• "Design and Rationale for a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate the Safety and Efficacy of CTP-499 in Patients with Diabetic Nephropathy; Publication in JASN Abstract Supplement; PUB195.

Source: Concert Pharmaceuticals